D'Alessandro N, Candiloro V, Crescimanno M, Flandina C, Dusonchet L, Crosta L, Rausa L
Pharmacol Res Commun. 1984 Feb;16(2):145-51. doi: 10.1016/s0031-6989(84)80089-2.
Catalase activity was followed up in the hearts and livers of CD 1 mice treated with Doxorubicin 4 mg/Kg, i.v., weekly for 9 weeks. In this murine model the antiblastic induces cardiac morphological lesions which are progressively severer with the increase of the administered cumulative dose. Heart catalase showed a consistent elevation which reached a maximum (+116.2%, P less than 0.05) after the 5th dose. In the case of hepatic catalase no significant variation was observed except a transitory elevation following the first administration. The specific increase of heart catalase activity following multiple Doxorubicin doses could be an indicator that an enhanced free radical generation acts "in vivo" along with the onset of the cardiac lesions due to antiblastic.
对体重为18-22克的CD-1小鼠静脉注射4毫克/千克阿霉素，每周一次，共9周，之后检测其心脏和肝脏中的过氧化氢酶活性。在该小鼠模型中，抗胚细胞药物会引发心脏形态学病变，且随着累积给药剂量的增加，病变会逐渐加重。心脏过氧化氢酶呈现持续升高，在第5次给药后达到最大值（升高116.2%，P<0.05）。对于肝脏过氧化氢酶，除首次给药后有短暂升高外，未观察到显著变化。多次给予阿霉素后心脏过氧化氢酶活性的特异性升高可能表明，随着抗胚细胞药物引起心脏病变的发生，体内自由基生成增加。
